Caroline Loew has been appointed president and CEO of Glympse Bio. Loew comes to the Cambridge, MA, company from Bristol-Myers Squibb (NYSE: [[ticker:BMY]]), where she was most recently vice president and head of R&D strategy and planning. Her experience also include positions at Merck (NYSE: [[ticker:MRK]]) and the Pharmaceutical Research and Manufacturers of America, a drug industry trade group. Glympse has developed nanotechnology sensors that it says can detect diseases at their earliest stages. In October, Glympse raised $22 million in Series A funding for clinical trials testing its sensors as a way of detecting the fatty liver disease nonalcoholic steatohepatitis.
